Lian­Bio an­nounces terms for IPO next week; NIH and White House of­fi­cials dis­cuss hy­po­thet­i­cal bio-med re­search agency

Lian­Bio, a biotech that has op­er­a­tions in both the US and Chi­na, an­nounced the terms yes­ter­day for its ini­tial pub­lic of­fer­ing.

The biotech plans to raise $325 mil­lion by of­fer­ing 20.3 mil­lion shares priced be­tween $15 and $17.

At the mid­point of the pro­posed range, Lian­Bio could com­mand a ful­ly di­lut­ed mar­ket val­ue of $1.8 bil­lion, based on a num­ber of ex­pect­ed out­stand­ing shares.

The two year old biotech has fo­cused on in-li­cens­ing and com­mer­cial­iza­tion of ther­a­peu­tics in Chi­na, Hong Kong, Tai­wan, Macau and oth­er Asian mar­kets. The com­pa­ny cur­rent­ly has nine pro­grams across five ther­a­peu­tic ar­eas, in­clud­ing on­col­o­gy, car­dio­vas­cu­lar, and in­flam­ma­to­ry dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.